Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SM3321 in Locally Advanced or Metastatic Solid Tumors
NCT06087770Phase 1Completed
- Sponsor
- Starmab Biologics
- Start
- Dec 2023
- Primary completion
- Oct 2024
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Nanobodies (VHH)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SM3321 in solid tumor, sponsored by Starmab Biologics. Primary endpoints: Maximum Tolerated Dose at 28 days, Recommended Phase 2 Dose at 28 days and 1 more. Started Dec 2023; status: completed.
02
Drugs
SM3321
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06087770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06087770.